Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- Prophylactic antibiotics.

- Tylenol (650 mg orally every 6 hours as needed for temperature > 38.5 degrees C).

- Meperidine (25 - 50 mg intravenously, once, for severe rigors if systolic blood
pressure is > 90 mmHg).

Patients must meet criteria for AIDS classification (CDC) category IV C-1.

- Patients must have had one or more prior opportunistic infections identified in
surveillance definition of AIDS. Patients whose AIDS-defining illness is Kaposi's
sarcoma are also eligible if they have previously had one of the secondary
infectious diseases identified in category C-1.

Prior Medication:

Required:

- Patients must have been receiving zidovudine (AZT) on a stable dosage regimen for at
least 8 weeks immediately preceding entry into study.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

- Clinically significant cardiac (= or > class II, New York Heart Association) or
peripheral vascular disease that requires treatment.

- Presence of an active opportunistic infection that requires treatment.

- Hemorrhagic diathesis or active bleeding disorder.

- Clinically apparent vascular disease.

Concurrent Medication:

Excluded:

- Medications required for treatment of active cardiac disease.

- Ongoing therapy with anticoagulants or thrombolytic agents.

Patients with the following are excluded:

- Clinically significant cardiac (= or > class II, New York Heart Association) or
peripheral vascular disease that requires treatment.

- Presence of an active opportunistic infection that requires treatment.

- Hemorrhagic diathesis or active bleeding disorder.

- Clinically apparent vascular disease.

Prior Medication:

Excluded within 4 weeks of study entry:

- Antiviral chemotherapy other than zidovudine.

- Excluded within 12 weeks of study entry:

- Immunosuppressive or cytotoxic therapy.